Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$6.73 - $9.05 $139,856 - $188,068
-20,781 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$6.61 - $10.07 $1,573 - $2,396
-238 Reduced 1.13%
20,781 $188,000
Q4 2020

Feb 11, 2021

SELL
$5.03 - $7.95 $2,922 - $4,618
-581 Reduced 2.69%
21,019 $140,000
Q3 2020

Nov 16, 2020

SELL
$5.02 - $8.98 $316 - $565
-63 Reduced 0.29%
21,600 $109,000
Q2 2020

Aug 14, 2020

BUY
$7.25 - $11.75 $48,894 - $79,242
6,744 Added 45.2%
21,663 $175,000
Q1 2020

May 14, 2020

SELL
$4.06 - $10.64 $2,805 - $7,352
-691 Reduced 4.43%
14,919 $118,000
Q4 2019

Feb 14, 2020

SELL
$3.34 - $7.7 $167 - $385
-50 Reduced 0.32%
15,610 $118,000
Q3 2019

Nov 13, 2019

BUY
$1.92 - $4.47 $26 - $62
14 Added 0.09%
15,660 $65,000
Q2 2019

Aug 13, 2019

SELL
$1.09 - $3.19 $1,284 - $3,757
-1,178 Reduced 7.0%
15,646 $45,000
Q1 2019

May 13, 2019

SELL
$1.44 - $3.29 $518 - $1,184
-360 Reduced 2.09%
16,824 $24,000
Q4 2018

Feb 12, 2019

SELL
$1.74 - $4.66 $612 - $1,640
-352 Reduced 2.01%
17,184 $44,000
Q3 2018

Nov 14, 2018

BUY
$4.08 - $7.14 $8,417 - $14,729
2,063 Added 13.33%
17,536 $77,000
Q2 2018

Sep 18, 2018

SELL
$5.89 - $7.78 $15,443 - $20,399
-2,622 Reduced 14.49%
15,473 $95,000
Q2 2018

Aug 14, 2018

BUY
$5.89 - $7.78 $24,879 - $32,862
4,224 Added 30.45%
18,095 $111,000
Q1 2018

May 09, 2018

SELL
$6.76 - $11.7 $2,034 - $3,521
-301 Reduced 2.12%
13,871 $101,000
Q4 2017

Feb 14, 2018

SELL
$8.03 - $11.25 $4,288 - $6,007
-534 Reduced 3.63%
14,172 $116,000
Q3 2017

Nov 13, 2017

BUY
$8.35 - $10.5 $122,795 - $154,413
14,706
14,706 $154,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $626M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.